Lamotrigine as add-on treatment (500 mg per day) is effective in patients with refractory epilepsy, but its high cost requires a pharmacoeconomic analysis.
We conducted a retrospective lifetime cost-utility study in which clinical data were derived from a recent placebo-controlled clinical trial, cost-of-illness data were drawn from a previous ad-hoc study, and quality-of-life values were obtained by prospectively interviewing a separate group of 81 patients referred to our institution with epilepsy.
Our analysis showed that chronic lamotrigine treatment implies an incremental lifetime cost of about $1 600 000 for every 100 patients.
Incremental lifetime utility was around 40 quality-adjusted life-years (QALYs) for every 100 patients.
On the basis of these data, adjunctive lamotrigine was estimated to cost approximately $41 000 per QALY gained.
Sensitivity testing suggested a range of $25 000-$85 000 per QALY gained.
Adjunctive lamotrigine (500 mg per day) in refractory epilepsy seems to have a worse pharmacoeconomic profile than many pharmacological treatments commonly used in areas other than epilepsy.
Further data are needed to determine if lamotrigine can be equally effective at lower (and less costly) daily doses which could markedly improve its pharmacoeconomic characteristics.
Mots-clés Pascal : Lamotrigine, Anticonvulsivant, Epilepsie, Résistance traitement, Chimiothérapie, Traitement, Homme, Qualité vie, Analyse coût efficacité, Economie santé, Coût, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie
Mots-clés Pascal anglais : Lamotrigine, Anticonvulsant, Epilepsy, Negative therapeutic reaction, Chemotherapy, Treatment, Human, Quality of life, Cost efficiency analysis, Health economy, Costs, Nervous system diseases, Central nervous system disease, Cerebral disorder
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0169691
Code Inist : 002B02B06. Création : 21/07/1998.